XRCC4: A Potential Drug Target for Disabilities and Diseases (G7518)

Target Name: XRCC4

NCBI ID: G7518

XRCC4

XRCC4: A Potential Drug Target for Disabilities and Diseases

XRCC4 (X-linked Recurrent Contactinosis Control Region gene 4) is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

XRCC4 is a member of the X-linked recurrent contactinosis control region gene family, which is characterized by the presence of a specific gene mutation that results in the development of contactinosis, a condition that involves the formation of cords or strands of DNA in the eyes that can cause blindness.

While contactinosis is most commonly associated with individuals who are carriers of the mutated gene, research has suggested that the condition can also be caused by exposure to environmental toxins or other factors.

XRCC4 has been shown to be involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

For example, studies have shown that XRCC4 mutations are frequently observed in individuals with neurofibromatosis, a genetic disorder that involves the formation of nerve fibers that can cause weakness, numbness, and other symptoms.

In addition, XRCC4 has also been implicated in the development of certain autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

The potential drug target for XRCC4 is based on the fact that the gene has been shown to be involved in the regulation of cell growth and differentiation, as well as in the development of certain diseases.

Research has suggested that XRCC4 mutations may disrupt the normal function of cells, leading to the development of certain diseases.

In addition, the fact that XRCC4 is located on the X chromosome has raised the possibility that it may be involved in sex-specific diseases, such as infertility orxenophilia.

While more research is needed to fully understand the role of XRCC4 in the development and progression of disease, the potential drug target is a promising area of 鈥嬧?媠tudy that may lead to new treatments for a variety of conditions.

Protein Name: X-ray Repair Cross Complementing 4

Functions: DNA non-homologous end joining (NHEJ) core factor, required for double-strand break repair and V(D)J recombination (PubMed:10757784, PubMed:10854421, PubMed:17124166, PubMed:16412978, PubMed:8548796, PubMed:25742519, PubMed:12517771, PubMed:17290226, PubMed:22228831, PubMed:25597996, PubMed:25934149, PubMed:26100018, PubMed:26774286). Acts as a scaffold protein that regulates recruitment of other proteins to DNA double-strand breaks (DSBs) (PubMed:15385968, PubMed:20852255, PubMed:26774286, PubMed:27437582). Associates with NHEJ1/XLF to form alternating helical filaments that bridge DNA and act like a bandage, holding together the broken DNA until it is repaired (PubMed:26100018, PubMed:27437582, PubMed:28500754, PubMed:21775435, PubMed:22287571, PubMed:21768349). The XRCC4-NHEJ1/XLF subcomplex binds to the DNA fragments of a DSB in a highly diffusive manner and robustly bridges two independent DNA molecules, holding the broken DNA fragments in close proximity to one other (PubMed:27437582). The mobility of the bridges ensures that the ends remain accessible for further processing by other repair factors (PubMed:27437582). Plays a key role in the NHEJ ligation step of the broken DNA during DSB repair via direct interaction with DNA ligase IV (LIG4): the LIG4-XRCC4 subcomplex reseals the DNA breaks after the gap filling is completed (PubMed:9242410, PubMed:10757784, PubMed:10854421, PubMed:12517771, PubMed:17290226, PubMed:19837014). XRCC4 stabilizes LIG4, regulates its subcellular localization and enhances LIG4's joining activity (PubMed:9242410, PubMed:10757784, PubMed:10854421, PubMed:12517771, PubMed:17290226, PubMed:21982441, PubMed:22228831). Binding of the LIG4-XRCC4 subcomplex to DNA ends is dependent on the assembly of the DNA-dependent protein kinase complex DNA-PK to these DNA ends (PubMed:10757784, PubMed:10854421). Promotes displacement of PNKP from processed strand break termini (PubMed:20852255, PubMed:28453785)

The "XRCC4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about XRCC4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets